Bpifrance Patient Autonome Fund

Overview

Bpifrance Patient Autonome Fund is a French sovereign wealth fund investing in startups, SMEs, and mid-caps in the connected health sector. Established in December 2017, the fund focuses on innovations that enhance patient autonomy through connected health solutions. It targets early-stage companies developing technologies in areas such as artificial intelligence for diagnostics, real-time disease monitoring, remote patient care, and improving the efficiency of healthcare pathways. The fund aims to identify and support the rapid and sustainable launch of these innovations in the market. With an initial capital of €50 million, the fund has invested in several companies, including Invivox, Nouveal e-santé, and Fizimed. In May 2021, the fund's size was doubled to €100 million, reflecting its commitment to accelerating the digital transformation of the French healthcare system. The fund's investments range from €500,000 to €3 million per company, with a maximum cumulative investment of €8 million. The fund collaborates with partners such as the Caisse Nationale de l'Assurance Maladie (CNAM) to validate market needs and support the development of business models for new healthcare solutions. This partnership aims to facilitate the adoption of innovative technologies in the healthcare sector and improve patient care efficiency. Bpifrance Patient Autonome Fund continues to play a pivotal role in fostering innovation within the French healthcare ecosystem, supporting companies that contribute to the modernization and efficiency of healthcare services through digital solutions.

Investment Focus

• Innovative solutions enhancing patient autonomy
• Technologies in diagnostics, disease monitoring, remote care
• Early-stage companies in the connected health sector

Portfolio Companies